

## Final - October 19, 2017

### MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention  
1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium  
Atlanta, Georgia 30329  
October 25-26, 2017

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(S)</u>
<b><u>Wednesday, October 25</u></b>		
<b>8:00 Welcome &amp; Introductions</b>		Dr. Nancy Bennett (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary; CDC)
<b>8:30 Herpes Zoster Vaccine</b>		
Introduction		Dr. Edward Belongia (ACIP, WG Chair)
Review of GRADE (ZVL, HZ/su)	Information &	Ms. Angela Guo (CDC/NCIRD)
Cost effectiveness analysis	Discussion	Dr. Lisa Prosser (University of Michigan)
Considerations and proposed recommendations		Dr. Kathleen Dooling (CDC/NCIRD)
<b>Public comment</b>		
Vote	<u>Vote</u>	Dr. Kathleen Dooling (CDC/NCIRD)
<b>10:30 Break</b>		
<b>10:45 Hepatitis Vaccines</b>		
Introduction		Dr. Arthur Reingold (ACIP, WG Chair)
HEPLISAV-B	Information &	Dr. Robert Janssen (Dynavax)
Work Group considerations: HEPLISAV-B	Discussion	Dr. Noele Nelson (CDC/NCHHSTP)
Hepatitis A outbreaks		Dr. Noele Nelson (CDC/NCHHSTP)
<b>12:15 Lunch</b>		
<b>1:15 Influenza Vaccines</b>		
Introduction		Dr. Chip Walter (ACIP, WG Chair)
Surveillance update		Ms. Lynnette Brammer (CDC/NCIRD)
Coverage update	Information &	Dr. Carla Black (CDC/NCIRD)
LAIV Efficacy/Effectiveness 2016-17 and strain selection update	Discussion	Dr. Raburn Mallory (MedImmune)
Vaccine Safety Datalink Pregnancy Study		Dr. James Donahue (Marshfield)
Work Group considerations: Influenza vaccines		Dr. Lisa Grohskopf (CDC/NCIRD)
<b>2:30 Break</b>		
<b>2:45 Mumps</b>		
Introduction		Dr. Kelly Moore (ACIP, WG Chair)
Update on mumps epidemiology in the United States	Information &	Dr. Mona Marin (CDC/NCIRD)
GRADE: third dose of MMR vaccine	Discussion	Dr. Mariel Marlow (CDC/NCIRD)
Considerations and proposed recommendations		Dr. Mona Marin (CDC/NCIRD)
<b>Public comment</b>		
Vote	<u>Vote</u>	Dr. Mona Marin (CDC/NCIRD)
VFC vote	<u>VFC Vote</u>	Dr. Jeanne Santoli (CDC/NCIRD)
<b>4:30 Vaccine Safety: Shoulder Injury After Vaccination</b>		
Introduction		Dr. Andrew Kroger (CDC/NCIRD)
Data from HRSA Vaccine Injury Compensation Claims	Information &	Dr. Narayan Nair (HRSA)
Data from the Vaccine Adverse Event Reporting System	Discussion	Dr. Tom Shimabukuro (CDC/NCEZID)
Communication and Education Campaign		Dr. Andrew Kroger (CDC/NCIRD)
<b>5:00 Human Papillomavirus (HPV) Vaccines Update</b>		
Introduction	Information	Dr. Peter Szilagyi (ACIP, WG Chair)
Update		Dr. Lauri Markowitz (CDC/NCIRD)
<b>5:15 Public Comment</b>		
<b>5:30 Adjourn</b>		

## Final - October 19, 2017

### Thursday, October 26

<b>8:00 Agency Updates &amp; Unfinished Business</b> CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO	Information	Dr. Nancy Messonnier (CDC/NCIRD); <i>Ex Officio</i> Members
<b>8:30 Adult Immunization Schedule</b> Introduction Proposed changes in the 2018 adult immunization schedule	<u>Vote</u>	Dr. Laura Riley (ACIP, WG Chair) Dr. David Kim (CDC/NCIRD)
<b>9:00 Child/Adolescent Immunization Schedule</b> Introduction Proposed 2018 child and adolescent schedule revisions	<u>Vote</u>	Dr. José Romero (ACIP, WG Chair) Dr. Candice Robinson (CDC/NCIRD)
<b>9:30 Japanese Encephalitis Vaccine</b> Introduction JE among U.S. travelers JE-VC post-marketing adverse event surveillance among U.S. military Adverse events following JE-VC reported to VAERS, 2012-2016 JE Vaccine Work Group summary and plans	Information & Discussion	Dr. Chip Walter (ACIP, WG Chair) Dr. Susan Hills (CDC/NCEZID) Dr. Christian Taucher (Valneva) Dr. Susan Hills (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID)
<b>10:30 Break</b>		
<b>10:50 Pneumococcal Vaccines</b> Introduction PCV13 impact on nasopharyngeal carriage among children and adults  PCV13 impact on invasive pneumococcal disease: update from Active Progress of the research agenda to inform potential policy change for	Information & Discussion	Dr. Arthur Reingold (ACIP, WG Chair) Dr. Fernanda Lessa (CDC/NCIRD), Ms. Stephanie M. Thomas (Emory University School of Medicine) Dr. Almea Matanock (CDC/NCIRD) Dr. Tamara Pilishvili (CDC/NCIRD)
<b>11:50 Anthrax Vaccines</b> Introduction Preparedness/Operational concerns Anthrax vaccine (BioThrax®) new safety and reactionogenicity data Information on immunogenicity and reactogenicity given by Summary	Information & Discussion	Dr. David Stephens (ACIP, WG Chair) Dr. William Bower (CDC/NCEZID) Dr. Kate Hendricks (CDC/NCEZID) Mr. Jarad Schiffer (CDC/NCIRD) Dr. William Bower (CDC/NCEZID)
<b>1:00 Evidence Based Recommendations</b>	Information	Dr. Wendy Carr (CDC/NCIRD)
<b>1:15 Respiratory Syncytial Virus (RSV) Vaccine</b>	Information	Dr. Gayle Langley (CDC/NCIRD)
<b>1:20 Vaccine Supply</b>	Information	Dr. Jeanne Santoli (CDC/NCIRD)
<b>1:25 Public Comment</b>		
<b>1:40 Adjourn</b>		

### **Acronyms**

<b>CDC</b>	Centers for Disease Control & Prevention
<b>CMS</b>	Centers for Medicare and Medicaid Services
<b>DoD</b>	Department of Defense
<b>DVA</b>	Department of Veterans Affairs
<b>FDA</b>	Food and Drug Administration
<b>GRADE</b>	Grading of Recommendations Assessment, Development and Evaluation
<b>HRSA</b>	Health Resources and Services Administration
<b>IHS</b>	Indian Health Service
<b>JE-VC</b>	Vero cell culture-derived Japanese encephalitis vaccine
<b>NCHHSTP</b>	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
<b>NCIRD</b>	National Center for Immunization & Respiratory Diseases [of CDC/OID]
<b>NCEZID</b>	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
<b>NVPO</b>	National Vaccine Program Office
<b>PCV13</b>	13-valent pneumococcal conjugate vaccine
<b>VFC</b>	Vaccines for Children
<b>WG</b>	Work Group